 |
12 Diseases |  |
14 Trials |
|
14 Trials |  |
524 News |  |
| «123456789» |
- Tivicay (dolutegravir) / ViiV Healthcare
Incidence of Metabolic Syndrome in People living with HIV Starting ART with a Dolutegravir Based-Regimen vs Bictegravir Based-Regimen After 24 Weeks in Mexico (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_813;
Method :
- Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare, Juluca (dolutegravir/rilpivirine) / ViiV Healthcare, J&J, Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
3-year analysis of emergent resistance-associated mutations at first- or second-line HIV-1 virologic failure with second generation INSTIs in 2- and 3-drug regimens (Virostar study) (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_728;
Sanger genotypic resistance assays were performed as part of standard clinical care at the time of a FL or SL VF in patients failing treatment with DTG/3TC, DTG/RPV, BIC/FTC/TAF and DTG/3TC/ABC. Conclusions :
- Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare, Juluca (dolutegravir/rilpivirine) / ViiV Healthcare, J&J, Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
3-year analysis of emergent resistance-associated mutations at first- or second-line HIV-1 virologic failure with second generation INSTIs in 2- and 3-drug regimens (Virostar study) (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_727;
Sanger genotypic resistance assays were performed as part of standard clinical care at the time of a FL or SL VF in patients failing treatment with DTG/3TC, DTG/RPV, BIC/FTC/TAF and DTG/3TC/ABC. Conclusions :
- Tivicay (dolutegravir) / ViiV Healthcare
Impact of pre-existing HIV-1 primary and secondary reverse transcriptase and integrase resistance-associated mutations by next generation sequencing on virological response to dolutegravir (DTG)-containing regimens in antiretroviral-na (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_716;
Resistance analyses in the 9 subjects with VF did not reveal any emergent resistance to the study drugs. Analyses of virological outcomes at weeks 48 and 96 did not find a significant role of pre-existing resistance in any of the analyzed groups (Fig.2) Conclusions :
- Tivicay (dolutegravir) / ViiV Healthcare
Impact of pre-existing HIV-1 primary and secondary reverse transcriptase and integrase resistance-associated mutations by next generation sequencing on virological response to dolutegravir (DTG)-containing regimens in antiretroviral-na (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_715;
Resistance analyses in the 9 subjects with VF did not reveal any emergent resistance to the study drugs. Analyses of virological outcomes at weeks 48 and 96 did not find a significant role of pre-existing resistance in any of the analyzed groups (Fig.2) Conclusions :
- Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Bictegravir/emtricitabine/tenofovir alafenamide vs. other regimens for initial therapy in late presenters with AIDS-defining conditions. (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_496;
Analyses of virological outcomes at weeks 48 and 96 did not find a significant role of pre-existing resistance in any of the analyzed groups (Fig.2) Conclusions : Analyzing single regimens, we observed differences in the rate of virological suppression between BIC/FTC/TAF and DTG/ABC/3TC both at 24 (ORa [95%CI]: 0.17 [0.04
- Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Bictegravir/emtricitabine/tenofovir alafenamide vs. other regimens for initial therapy in late presenters with AIDS-defining conditions. (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_495;
Analyzing single regimens, we observed differences in the rate of virological suppression between BIC/FTC/TAF and DTG/ABC/3TC both at 24 (ORa [95%CI]: 0.17 [0.04 Analyzing single regimens, we observed differences in the rate of virological suppression between BIC/FTC/TAF and DTG/ABC/3TC both at 24 (ORa [95%CI]: 0.17 [0.04
- Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare, Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Incidence of non-alcoholic fatty liver disease in antiretroviral therapy-na (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_490;
Analyzing single regimens, we observed differences in the rate of virological suppression between BIC/FTC/TAF and DTG/ABC/3TC both at 24 (ORa [95%CI]: 0.17 [0.04 Purpose :
- Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare, Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Incidence of non-alcoholic fatty liver disease in antiretroviral therapy-na (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_489;
Purpose : Purpose :
- | Tivicay (dolutegravir) / ViiV Healthcare
Journal: Alternative dolutegravir dosing strategies with concurrent rifapentine utilized for latent tuberculosis treatment. (Pubmed Central) - Sep 13, 2023
Purpose : The patient had baseline suppressed HIV viral load on fixed dose combination dolutegravir/abacavir/lamivudine when once-weekly rifapentine 900
- Rates and reasons for antiretroviral switches with implicated drug associations: a post-COVID 10-year comparison (ETIUDA) - Sep 10, 2023 - Abstract #EACS2023EACS_311;
Other reasons included simplification (17%), of which 40% were Triumeq to Dovato, virological failure (3%) and other...Bictegravir, raltegravir, darunavir and other antiretrovirals each accounted for 4%, and the associated drug was unknown in 1%...Efavirenz is still associated with the highest number of toxicity-related switches, however, switches from tenofovir have doubled, possibly due to the introduction of tenofovir alafenamide and two-drug regimens. The introduction of dolutegravir and doravirine has highlighted new toxicities.
- | Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare, Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
Journal, Real-world evidence, Real-world: Lipid profile changes associated with antiretroviral therapies in a real-world cohort. (Pubmed Central) - Sep 8, 2023
The introduction of dolutegravir and doravirine has highlighted new toxicities. The lipid profile among elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fumarate group worsened throughout the follow-up, both in na
- Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Real-World Effectiveness and Tolerability of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Treatment-Experienced People With HIV and a History of Antiretroviral Drug Resistance Mutations (Hall B + C) - Sep 6, 2023 - Abstract #IDWeek2023IDWeek_3001;
- Retrospective Study Comparing the Rate of HIV Blips With Combined Antiretroviral Therapy (Hall B + C) - Sep 6, 2023 - Abstract #IDWeek2023IDWeek_2974;
- ||| Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare
Trial completion date: FLAIR: Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants (clinicaltrials.gov) - Aug 31, 2023
P3, N=631, Active, not recruiting, Sponsor: ViiV Healthcare
The lipid profile among elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fumarate group worsened throughout the follow-up, both in na Trial completion date: Feb 2024 --> Dec 2026
- || Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare
P1/2 data, PK/PD data, Clinical Trial,Phase I, Journal: Pharmacokinetics, safety, and tolerability of dispersible and immediate-release abacavir, dolutegravir, and lamivudine tablets in children with HIV (IMPAACT 2019): week 24 results of an open-label, multicentre, phase 1-2 dose-confirmation study. (Pubmed Central) - Aug 9, 2023
P1/2
Dosing of abacavir, dolutegravir, and lamivudine was confirmed in children weighing 6 kg to less than 40 kg, and both FDC formulations were safe, well tolerated, and efficacious through 24 weeks of treatment. These findings support global efforts to expand the availability of FDC abacavir, dolutegravir, and lamivudine to children with HIV.
- | Dovato (dolutegravir/lamivudine) / ViiV Healthcare
Journal, HEOR, Real-world evidence, Real-world: Comparing Real-World Healthcare Costs Associated with Single-Tablet Regimens for HIV-1: The 2-Drug Regimen Dolutegravir/Lamivudine vs. Standard 3- or 4-Drug Regimens. (Pubmed Central) - Aug 8, 2023
These findings support global efforts to expand the availability of FDC abacavir, dolutegravir, and lamivudine to children with HIV. Dolutegravir/lamivudine had the lowest healthcare costs of BIC/FTC/TAF, EVG/COBI/FTC/TAF, and DRV/COBI/FTC/TAF, and the lowest pharmacy costs of all regimens, in unadjusted and adjusted analyses and by treatment experience, supporting the economic benefits of DTG/3TC as an initial or switch regimen for HIV-1.
- Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare, Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Disseminated Histoplasmosis: A Gastrointestinal Manifestation (Exhibit Hall) - Jul 29, 2023 - Abstract #ACG2023ACG_3946;
It is important to note that HIV patients with HBV who stop antiretroviral agents that have activity against HBV (like Truvada, or Triumeq), are at higher risk of hep B reactivation, particularly HBV-related immune reconstitution. Figure: Patient's EGD which showed ulcerated mass with active bleeding in the 2nd portion of duodenum.
- || Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare
P4 data, Journal: A Korean Post-Marketing Study of Abacavir/Dolutegravir/Lamivudine in Patients with HIV-1. (Pubmed Central) - Jun 5, 2023
Figure: Patient's EGD which showed ulcerated mass with active bleeding in the 2nd portion of duodenum. Results of this PMS study showed that abacavir/dolutegravir/lamivudine administered as highly active antiretroviral therapy was well tolerated and effective in patients with HIV-1 infection.
- | Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare, Dovato (dolutegravir/lamivudine) / ViiV Healthcare
Journal: Effect of Food on the Pediatric Dispersible Tablet Formulations of TRIUMEQ and DOVATO in Healthy Adult Participants. (Pubmed Central) - May 27, 2023
Safety observations were similar for both treatments, either in the fed or fasted state. Both TRIUMEQ DT and DOVATO DT formulations can be administer with or without food.
- | Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Journal: Bictegravir/emtricitabine/tenofovir alafenamide as initial treatment for HIV-1: five-year follow-up from two randomized trials. (Pubmed Central) - May 18, 2023
P3
Both TRIUMEQ DT and DOVATO DT formulations can be administer with or without food. The safety and efficacy of B/F/TAF as initial therapy was established in two Phase 3 studies: 1489 (vs dolutegravir [DTG]/abacavir/lamivudine) and 1490 (vs DTG
- Probability of single tablet regimens BIC/FTC/TAF, E/C/F/TAF, RPV/FTC/TAF, DTG/RPV or DTG/ABC/3TC discontinuation at 18 months in real life settings in the ANRS-CO3 - AquiVIH-NA cohort () - May 5, 2023 - Abstract #IASHIV2023IAS_HIV_1476;
The safety and efficacy of B/F/TAF as initial therapy was established in two Phase 3 studies: 1489 (vs dolutegravir [DTG]/abacavir/lamivudine) and 1490 (vs DTG Embargoes on oral abstracts and posters lift on Monday, 24 July 2023, at 09:00 Australian Eastern Standard Time (AEST).
- || Dovato (dolutegravir/lamivudine) / ViiV Healthcare, Tivicay (dolutegravir) / ViiV Healthcare
Review, Journal: An indirect comparison of 144-week efficacy, safety, and tolerability of dolutegravir plus lamivudine and second-generation integrase inhibitor-based, 3-drug, single-tablet regimens in therapy-naive people with HIV-1. (Pubmed Central) - Mar 25, 2023
Embargoes on oral abstracts and posters lift on Monday, 24 July 2023, at 09:00 Australian Eastern Standard Time (AEST). These results suggest that the 2-drug regimen DTG?+?3TC offers comparable and durable efficacy with fewer serious adverse events vs BIC/FTC/TAF and DTG/ABC/3TC through 144
- bictegravir (GS-9883) / Gilead, Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Cost-Utility of Bictegravir/Tenofovir Alafenamide/Emtricitabine in Naive Patients over 18 Years of Age Living with Human Immunodeficiency Virus Type 1 Infection, from the Colombian () - Mar 9, 2023 - Abstract #ISPOR2023ISPOR_1650;
BIC/TAF/FTC is cost-effective compared to DTG/TAF/FTC and EVG/c/TAF/FTC with an incremental cost-effectiveness ratios of COP 25,423,858/QALY and COP 46,848,852/QALY, respectively. In naive patients over 18 years of age living with HIV-1 infection, BIC/TAF/FTC versus other triple combination antiretroviral therapies is a cost-effective technology for the Colombian health system.
- Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare, Tivicay (dolutegravir) / ViiV Healthcare, Fuzeon (enfuvirtide) / Roche
CLINICAL PHARMACEUTICAL CHALLENGES OF A BONE MARROW TRANSPLANT (BMT) PATIENT WITH HUMAN IMMUNODEFICIENCY VIRUS (HIV): A PAEDIATRIC PHARMACISTS PERSPECTIVE (ePoster Area) - Feb 11, 2023 - Abstract #EBMT2023EBMT_1708;
In naive patients over 18 years of age living with HIV-1 infection, BIC/TAF/FTC versus other triple combination antiretroviral therapies is a cost-effective technology for the Colombian health system. Admitted for BMT.Pharmacist-led ARV management plan in place within the conditioning protocol, with MDT approved recommendations if;Mucositis develops to reduce enteral absorptionNasogastric (NG) feeding or oral electrolytes requiredManagement plan created liaising with HIV team.Patient continued on current ARV regimen:Triumeq
- || Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare
P4 data, Journal: Virological Outcomes After Switching to Abacavir/Lamivudine/Dolutegravir Combined with Adherence Support in People Living with HIV with Poor Adherence: A Phase IV, Multicentre Randomized Prospective Open Label Study (TriiADD-CTN 286). (Pubmed Central) - Dec 21, 2022
Beyond treatment simplicity and tolerability, tailored interventions addressing stigma and social determinants of health are still needed. The numerous challenges we encountered illustrate how randomised trials may not be the best approach for assessing adherence interventions in vulnerable populations.
- || Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare
Interesting study from our CVIS group Virological Outcomes After Switching to Abacavir/Lamivudine/Dolutegravir Combined with Adherence Support in People … https://t.co/V6vwzafwvi (Twitter) - Dec 20, 2022
- || Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Clinical, Retrospective data, Journal: Comparison of Virological Efficacy of DTG/ABC/3TG and B/F/TAF Regimens and Discontinuation Patterns in Persons Living with Advanced HIV in the Era of Rapid ART: A Retrospective Multicenter Cohort Study. (Pubmed Central) - Dec 16, 2022
In the real world, the risk of regimen discontinuation was higher in PLWAH on coformulated DTG/ABC/3TC than in those on B/F/TAF, with no difference in viral suppression or virological failure. Given the findings concerning the effect of same-day ART prescription and AOIs on AR-related regimen discontinuation, individualized approaches to PLWAH are necessary.
- || Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare, abacavir/lamivudine / Generic mfg.
Dolutegravir abacavir lamivudine can surpess to below 50 VL in only 16 weeks ❤️. Does the abacavir play significant role? I am having TDF instead of it (Twitter) - Dec 9, 2022
- | Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare, Descovy (emtricitabine/tenofovir alafenamide) / Gilead, Vitekta (elvitegravir) / Japan Tobacco, Gilead
Retrospective data, Journal: Weight changes after first-line antiretroviral initiation in a cohort of HIV-positive patients in Southern Spain (CAPOTA study). (Pubmed Central) - Nov 15, 2022
After ART initiation patients gain weight regardless of the regimen they take. Weight gain is associated with AIDS and the use of TAF/FTC/EVG/c.
- | abacavir / Generic mfg.
Journal: Severe abacavir hypersensitivity reaction in a patient with human immunodeficiency virus infection: a case report. (Pubmed Central) - Nov 9, 2022
Clinicians should always be cognizant of this adverse reaction whenever they initiate an abacavir-containing therapy. We would recommend that studies be done in our setting to verify the prevalence of HLA-B*57:01.
- | Tivicay (dolutegravir) / ViiV Healthcare
Journal: HIV-1 resistance against dolutegravir fluctuates rapidly alongside erratic treatment adherence: a case report. (Pubmed Central) - Nov 9, 2022
This case illustrates how poorly-fit drug-resistant viruses wax and wane alongside erratic treatment adherence and are easily misdiagnosed by Sanger sequencing. We recommend next-generation sequencing to improve the clinical management of incomplete virological suppression with dolutegravir.
- | Dovato (dolutegravir/lamivudine) / ViiV Healthcare
Biomarker, Journal: Changes in inflammatory biomarkers when switching from from 3-drug regimens to dolutegravir plus lamivudine in people living with HIV. (Pubmed Central) - Oct 28, 2022
Analysis of only individuals who switched from ABC/3TC/DTG, TAF-based regimens also showed no significant changes in inflammatory markers. Since viremia raises inflammatory markers, differences in antiviral efficacy may make a difference in the suppression of chronic inflammation but in conclusion, we did not find any change in inflammatory markers by changing from 3DR to 2DR in daily clinical practice.
- The Virostar study: analysis of emergent resistance-associated mutations at first- or second-line HIV-1 virological failure with second-generation InSTIs in two- and three-drug regimens () - Oct 4, 2022 - Abstract #HIVGlasgow2022HIV_Glasgow_349;
Rare emergent InSTI RAMs and few emergent NRTI RAMs were detected in patients failing DTG+3TC and DTG- or BIC-based 3DR at a first- or second-line VF in real-world settings. More emergent NNRTI RAMs were detected with failure of DTG+RPV.
- Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare, Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
The effects of switching from dolutegravir/abacavir/lamivudine to bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed people living with HIV on neuropsychiatric symptoms: preliminary findings from a randomised study () - Oct 4, 2022 - Abstract #HIVGlasgow2022HIV_Glasgow_297;
Switch from DTG/ABC/3TC to B/F/TAF in virologically suppressed PLWHIV was associated with improvement in two reported symptoms. Further data from the 12-month study follow-up are required to evaluate the potential impact on the incidence and severity of neuropsychiatric symptoms of treatment switch to B/F/TAF compared to continued DTG/ABC/3TC.
- Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare, Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead, Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Switch to bictegravir in real-life settings in the ANRS-CO3-AquiVIH-NA cohort () - Oct 4, 2022 - Abstract #HIVGlasgow2022HIV_Glasgow_224;
Virological failure was observed in 3% of patients. The switch to BIC/FTC/TAF in virologically suppressed patients is a safe and effective strategy.
- Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare, Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Outcomes after switching from 144 weeks of blinded DTG/ABC/3TC or DTG+F/TAF to 96 weeks of open-label B/F/TAF () - Oct 4, 2022 - Abstract #HIVGlasgow2022HIV_Glasgow_215;
These results provide additional long-term evidence of the safety and efficacy of B/F/TAF in those who switch from a DTG-containing regimen. aDefined as the last non-missing value obtained on or prior to the first dose of open-label B/F/TAF; bfrom time of B/F/TAF start.
- Dovato (dolutegravir/lamivudine) / ViiV Healthcare
Real-world use of dolutegravir/lamivudine in treatment-naïve people living with HIV during the COVID pandemic () - Oct 4, 2022 - Abstract #HIVGlasgow2022HIV_Glasgow_185;
Many D/Cs were actually gaps in prescriptions, with nearly a third returning to the initial regimen. Such ART prescription patterns may be an anomaly of the COVID-19 pandemic.
- Dovato (dolutegravir/lamivudine) / ViiV Healthcare
Could Dolutegravir/Lamivudine be a valid dual-therapy option even in pregnancy? Data from a retrospective analysis () - Oct 4, 2022 - Abstract #HIVGlasgow2022HIV_Glasgow_134;
The DTG/3TC regimen may represent a therapeutic option in patients in whom, for various reasons, DTG+2NRTI regimen is not indicated. Further data and studies are needed to support the evidence of efficacy and safety of DTG/3TC in pregnancy.
- ||| Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare
Trial completion, Trial completion date: IMPAACT 2019: The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age (clinicaltrials.gov) - Oct 3, 2022
P1/2, N=57, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Further data and studies are needed to support the evidence of efficacy and safety of DTG/3TC in pregnancy. Active, not recruiting --> Completed | Trial completion date: Jun 2024 --> Jun 2022
- | Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare
Its the Triumeq study I believe. (Twitter) - Sep 30, 2022
- ||||||| Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare
Trial completion: A Study to Determine Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) in Human Immunodeficiency Virus (HIV)-1 Infected Antiretroviral Therapy (ART) Na (clinicaltrials.gov) - Sep 29, 2022
P3, N=499, Completed, Sponsor: ViiV Healthcare
Active, not recruiting --> Completed | Trial completion date: Jun 2024 --> Jun 2022 Active, not recruiting --> Completed
- | Journal: Changes in Quality of Sleep, Mood, and Other Neuropsychiatric Symptoms After Switching Dolutegravir/Lamivudine/Abacavir to Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in a Randomized Study of People With Human Immunodeficiency Virus With Poor Sleep Quality: GESIDA 10418. (Pubmed Central) - Sep 24, 2022
At weeks 4 and 8 after all participants switched to darunavir/cobicistat/emtricitabine/tenofovir alafenamide, we have observed significant improvements in PSQI and HAD scores and in NS. In patients reporting subclinical sleep disturbances without insomnia, switching from dolutegravir/lamivudine/abacavir to darunavir/cobicistat/emtricitabine/tenofovir alafenamide was associated with better sleep quality and improvements in mood and NS.
- ||| Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare
We intensified to abc/3tc/dtg+bid drv/r+ mvc, and used DTG 150mg/day. We intensified cuz his cd4 counts were below 30 for 2 years with LLV and he had dMAC, CMV retinitis, PCP and cachexia. He eventually reconstituted his cd4 and suppressed his viral load. He’s down to triumeq. (Twitter) - Sep 18, 2022
- Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
5-year outcomes of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) as initial treatment of HIV-1 in adults with high baseline HIV-1 RNA and/or low CD4 count in two Phase 3 randomized clinical trials (Hall B + C) - Sep 8, 2022 - Abstract #IDWeek2022IDWEEK_1801;
- | Edurant (rilpivirine) / J&J
Observational data, Journal: HIV-1 RNA levels in rectal and seminal compartments after switching to long-acting cabotegravir plus rilpivirine: a longitudinal study. (Pubmed Central) - Aug 25, 2022
HIV-1 RNA levels were longitudinally evaluated in 211 rectal and 152 seminal samples from 12 virologically-suppressed participants switching to monthly long-acting cabotegravir plus rilpivirine or continuing with daily dolutegravir-abacavir-lamivudine. Maintenance of viral suppression in rectal and seminal compartments was comparable and blips occurred with similar frequency with both treatment regimens.
- | Journal: Major revision version 11.0 of the European AIDS Clinical Society Guidelines 2021. (Pubmed Central) - Aug 17, 2022
In 2021, the EACS Guidelines were updated extensively and broadened to include new sections. The recommendations are available as a free app, in interactive web format and as an online pdf.
- | Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare, Descovy (emtricitabine/tenofovir alafenamide) / Gilead
Journal: Weight Gain and Lipid Profile Changes in Koreans with Human Immunodeficiency Virus undergoing Integrase Strand Transfer Inhibitor-Based Regimens. (Pubmed Central) - Aug 4, 2022
Exercise, together with demographic-, HIV-, and anti-retroviral therapy-related factors, influenced weight gain. Therefore, when prescribing an INSTI-based STR, weight gain and metabolic changes should be closely monitored in PLWH with these risk factors.
- | Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare, Prezcobix (darunavir/cobicistat) / Gilead, J&J, Tivicay (dolutegravir) / ViiV Healthcare
Journal: Immunological and inflammatory changes after simplifying to dual therapy in virologically suppressed HIV-infected patients through week 96 in a randomized trial. (Pubmed Central) - Jul 28, 2022
Therefore, when prescribing an INSTI-based STR, weight gain and metabolic changes should be closely monitored in PLWH with these risk factors. Both IR and IA/I, CA-DNA, and usRNA were similar in the three treatment groups, regardless of maintaining TT or simplifying to DTG/3TC or DRVc/3TC in virologically suppressed HIV-infected patients.
- | Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare
Enrollment open: Moso: Point-of-Care HIV Testing and Early Dolutegravir Use for Infants (clinicaltrials.gov) - Jul 7, 2022
P4, N=900, Recruiting, Sponsor: Harvard School of Public Health (HSPH)
Both IR and IA/I, CA-DNA, and usRNA were similar in the three treatment groups, regardless of maintaining TT or simplifying to DTG/3TC or DRVc/3TC in virologically suppressed HIV-infected patients. Not yet recruiting --> Recruiting